Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers

The sodium glucose co‐transporter‐2 inhibitor dapagliflozin has been shown to decrease urinary albumin‐to‐creatinine ratio (UACR). This effect, however, varies among individual patients. In this study, we assessed the baseline characteristics and concurrent changes in other cardiovascular risk marke...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Obes Metab
Main Authors: Heerspink, Hiddo J. L., Sjöström, C. David, Inzucchi, Silvio E., Hallow, Melissa K., Cain, Valerie A., Rossing, Peter, Stefansson, Bergur V., Sartipy, Peter
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2018
Assuntos:
Brief Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6590413/
https://ncbi.nlm.nih.gov/pubmed/30414240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13579
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados